Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$613.69 USD
-6.56 (-1.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $613.82 +0.13 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$613.69 USD
-6.56 (-1.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $613.82 +0.13 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.
Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q3
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.
CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.
Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
by Zacks Equity Research
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.
Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.
Patterson Cos. (PDCO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2
Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Inogen (INGN) saw growth in revenues within its Rental segment in Q2.
QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.
Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract
by Zacks Equity Research
Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
by Zacks Equity Research
LabCorp's (LH) COVID-19 related research too has been progressing well.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.
Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.